Dataset Information

Sclerin, a New Cytotoxic Cyclononapeptide from Annona scleroderma.

ABSTRACT: A new cytotoxic cyclononapeptide, sclerin, cyclo(⁻Dab¹⁻Ser²⁻Tyr³⁻Gly⁴⁻Thr⁵⁻Val⁶⁻Ala⁷⁻ Ile⁸⁻Pro⁸⁻) (1), was isolated from the methanol extract of the seeds of Annona scleroderma, together with the known metabolite, cyclosenegalin A, cyclo(⁻Pro¹⁻Gly²⁻Leu³⁻Ser⁴⁻Ala⁵⁻Val⁶⁻Thr⁷⁻) (2). The planar structures for the two compounds were established by comprehensive analysis of NMR and ESI-HRMS data, and the absolute stereochemistry was stablished by Marfey's method. Compound 1 showed moderate cytotoxic activity against the human prostate carcinoma cell line DU-145 at µM concentration.

SUBMITTER: Cen-Pacheco F

PROVIDER: S-EPMC6384883 | biostudies-other | 2019 Feb

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Sclerin, a New Cytotoxic Cyclononapeptide from Annona scleroderma.

Cen-Pacheco Francisco F Valerio-Alfaro Gerardo G Santos-Luna Dalia D Fernández José Javier JJ

Molecules (Basel, Switzerland) 20190203 3

A new cytotoxic cyclononapeptide, sclerin, cyclo(⁻Dab¹⁻Ser²⁻Tyr³⁻Gly⁴⁻Thr⁵⁻Val⁶⁻Ala⁷⁻ Ile⁸⁻Pro⁸⁻) (1), was isolated from the methanol extract of the seeds of Annona scleroderma, together with the known metabolite, cyclosenegalin A, cyclo(⁻Pro¹⁻Gly²⁻Leu³⁻Ser⁴⁻Ala⁵⁻Val⁶⁻Thr⁷⁻) (2). The planar structures for the two compounds were established by comprehensive analysis ...[more]

PMID: 30717439

Similar Datasets

Project description:Introduction/objectivesScleroderma is a rare complication in taxanes therapy. Although individual cases of taxanes-induced scleroderma have been reported, the clinical manifestation and treatment outcomes were reviewed and summarized rarely. This study reported a patient who developed diffuse scleroderma and possible scleroderma renal crisis after paclitaxel therapy for ureter cancer.MethodA PubMed literature review on published cases of taxanes-induced scleroderma up until April 2022 was included for analysis.ResultsThe search identified 27 patients with adequate information for analysis. Of the 28 patients, including the one presented here, 22 were female. Peripheral edema was the most common symptom in all but one patient, and often accompanied by erythema in 11. Symptoms usually occurred in half of the patients within the 4th course of treatment. Skin lesions gradually progressed to skin fibrosis, and extended proximally. Internal organ involvements were uncommon. Antinuclear antibody tests were positive occasionally, but anti-Scl70 and anti-centromere usually were negative. Taxanes therapy was discontinued, continued and unavailable in 21, 3, and 4 patients, respectively. Corticosteroids for skin lesions with or without immunosuppressive drugs were given to 15 patients. Of 25 patients with available skin outcomes, 19 improved. There was no significant skin improvement between those who did or did not receive skin treatment (62.5% vs. 75.0%, p = 0.37). Skin usually improved after discontinuing taxanes.ConclusionTaxanes-induced scleroderma is different from idiopathic scleroderma. Physicians should be aware of this condition in order to provide early diagnosis and apply appropriate management in order to avoid serious complications from severe skin sclerosis. Key Points • Scleroderma is a rare but unique and serious complication of taxanes therapy • Skin manifestations and distribution are similar to idiopathic scleroderma, but vascular phenomenon, internal organ involvement and scleroderma-associated auto-antibodies are presented rarely. Skin improvement usually occurs shortly after discontinuing taxanes • The role of immunosuppressive therapy in treating taxanes-induced scleroderma is not clear.

Dataset Information

Sclerin, a New Cytotoxic Cyclononapeptide from Annona scleroderma.

Publications

Sclerin, a New Cytotoxic Cyclononapeptide from <i>Annona scleroderma</i>.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets